150.09
price down icon1.35%   -2.055
after-market Dopo l'orario di chiusura: 150.09
loading

Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie

pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 18, 2025

Autohome ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Inkl

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl

Feb 18, 2025
pulisher
Feb 17, 2025

Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com

Feb 17, 2025
pulisher
Feb 13, 2025

ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 13, 2025
pulisher
Feb 12, 2025

Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Ascendis Pharma launches $25 million share buyback - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView

Feb 12, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com

Feb 11, 2025
pulisher
Feb 03, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN

Feb 03, 2025
pulisher
Jan 29, 2025

JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com

Jan 29, 2025
pulisher
Jan 29, 2025

Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World

Jan 29, 2025
pulisher
Jan 15, 2025

Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com

Jan 15, 2025
pulisher
Jan 13, 2025

BioMarin sues Ascendis Pharma over patent infringement - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com

Jan 13, 2025
pulisher
Jan 12, 2025

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN

Jan 12, 2025
pulisher
Jan 07, 2025

European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN

Jan 07, 2025
pulisher
Jan 07, 2025

UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com

Jan 07, 2025
pulisher
Dec 31, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN

Dec 31, 2024
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN

Dec 29, 2024
pulisher
Dec 20, 2024

Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN

Dec 18, 2024
pulisher
Dec 16, 2024

Ascendis Pharma target raised to $194 on positive trial results - Investing.com

Dec 16, 2024
pulisher
Dec 07, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN

Dec 07, 2024
pulisher
Nov 21, 2024

Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN

Nov 20, 2024
pulisher
Oct 21, 2024

TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com

Oct 21, 2024
pulisher
Oct 14, 2024

Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 09, 2024

Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex

Oct 09, 2024
pulisher
Oct 01, 2024

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily

Oct 01, 2024
pulisher
Sep 30, 2024

Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com

Sep 30, 2024
pulisher
Sep 25, 2024

Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News

Sep 25, 2024
pulisher
Sep 18, 2024

Ascendis Pharma launches $300 million public offering - Investing.com

Sep 18, 2024
pulisher
Sep 16, 2024

Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com

Sep 16, 2024
pulisher
Sep 10, 2024

Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com

Sep 10, 2024
pulisher
Sep 09, 2024

A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News

Sep 09, 2024
pulisher
Sep 04, 2024

Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily

Sep 04, 2024
pulisher
Sep 03, 2024

Ascendis Pharma secures $150 million royalty deal for YORVIPATH - Investing.com

Sep 03, 2024
pulisher
Aug 22, 2024

3 George Soros stocks to turn $100 into $1,000 by 2025Finbold - Finbold - Finance in Bold

Aug 22, 2024
pulisher
Aug 21, 2024

JPMorgan raises Ascendis Pharma stock target on drug approval - Investing.com

Aug 21, 2024
pulisher
Aug 14, 2024

Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? - MSN

Aug 14, 2024
pulisher
Aug 13, 2024

Ascendis Pharma ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Aug 13, 2024
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):